X4 Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

X4 Pharmaceuticals

21/03/2024 13:32

* X4 Pharmaceuticals Inc  XFOR.OQ  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -29 cents.  The mean expectation of
seven analysts for the quarter was for a loss of 15 cents per
share. Wall Street expected results to range from -17 cents
to -14 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * X4 Pharmaceuticals Inc's reported EPS for the quarter was
a loss
of 10 cents​.
    * The company reported a quarterly loss of $19.13 million.
    * X4 Pharmaceuticals Inc shares had risen by 21.6% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for X4
Pharmaceuticals Inc is $3.00 

This summary was machine generated from LSEG data March 21 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.15          -0.10          Beat
 Sep. 30 2023      -0.15          -0.01          Beat
 Jun. 30 2023      -0.16          -0.33          Missed
 Mar. 31 2023      -0.22          -0.16          Beat